The approval expands the eligible patient population for the therapy in India and allows AstraZeneca to market the drug for the additional indication, subject to any other required statutory clearances.
The approval expands the eligible patient population for the therapy in India and allows AstraZeneca to market the drug for the additional indication, subject to any other required statutory clearances.